Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04919109 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
A Phase 1 study of Respiratory Syncytial Virus Infections, sponsored by Codagenix.
- Active
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 5
- Study locations
NCT04919109 is a Phase 1 study of Respiratory Syncytial Virus Infections that is active but no longer recruiting, run by Codagenix. The registered enrollment target is 51 participants, below the 1,089-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04919109, a Phase 1 study of Respiratory Syncytial Virus Infections, is active but no longer recruiting, sponsored by Codagenix.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety of and immune response to CodaVax-RSV in healthy children. They will be vaccinated in spring to early autumn 2023 and followed through the 2023-24 RSV season. 18 children aged 2 to 5 years who are RSV-seropositive (have antibodies to RSV) and 33 children aged 6 months to \< 2 years who are RSV-seronegative (do not have antibodies to RSV) will be enrolled in escalating-dose cohorts. A safety committee will review the safety profile of each dosing group before the next dose-escalation. Children will receive 2 doses of the vaccine at one of several dose levels or placebo (saline solution with no active ingredient) as nose drops; doses will be 28 days apart. A parent/guardian will record temperature and other conditions in a diary daily for 7 days after each dose. The parent/guardian will be contacted by telephone on the day after Dose 1 for safety assessment and review of the diary data. Children will return to the clinic 3, 7, 14, and 28 days after each dose. The parent/guardian will then be contacted by telephone monthly until 1 year after the second dose. Study procedures include physical examinations, vital signs, and collections of blood and nose/throat swab samples to look at safety of the vaccine and to analyze body's immune response.
Conditions Studied
Interventions
- BIOLOGICAL Normal Saline
- BIOLOGICAL CodaVax-RSV
Study Locations (5)
Nebraska
- Velocity - Lincoln
- Velocity - Omaha
Rhode Island
- Velocity - Providence
Utah
- Velocity - West Jordan
Other
- University of Witwatersrand (WITS)/Vaccines and Infectious Diseases Analytics (VIDA) - Johannesburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2025-08-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04919109
The ClinicalTrials.gov registry entry for NCT04919109 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,089-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (95% lower). The listed sponsor is Codagenix, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT04919109 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Nebraska, Rhode Island, Utah.
Frequently Asked Questions
What is clinical trial NCT04919109 about?
NCT04919109 is a clinical study titled "Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children". This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety of and immune response to CodaVax-RSV in healthy children. They will be vaccinated in spring to early autumn 2023 and followed through the 2023-24 RSV season. 18 children aged...
What is the current status of trial NCT04919109?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2023-03-28. Estimated completion is 2025-08-27.
What conditions does trial NCT04919109 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT04919109?
The interventions under investigation include: Normal Saline (BIOLOGICAL), CodaVax-RSV (BIOLOGICAL).
Who is sponsoring clinical trial NCT04919109?
This trial is sponsored by Codagenix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04919109 being conducted?
This trial has 5 study locations across Nebraska, Rhode Island, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of BLB-201 RSV Vaccine in Infants and Children
RECRUITING · Phase 1
-
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
COMPLETED · Phase 1
-
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
COMPLETED · Phase 1
-
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
COMPLETED · Phase 1
-
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.